Difference between revisions of "From Review Papers"
imported>조우빈 (Created page with "<p> </p> <p><a href="http://www.nature.com/nature/journal/v537/n7620/pdf/nature19949.pdf">http://www.nature.com/nature/journal/v537/n7620/pdf/nature19949.pdf</a></p> <p>(M...") |
imported>조우빈 |
||
| Line 4: | Line 4: | ||
<p>(Mass-Spectrometric exploration of proteome structure and function)</p> | <p>(Mass-Spectrometric exploration of proteome structure and function)</p> | ||
| + | |||
| + | <p>-> Provide unprecedented insights into the composition, structure, function and control of the proteome, shedding light on complex biological processes and phenotypes.</p> | ||
| + | |||
| + | <p>- Mass-Spectrometry-based methods</p> | ||
| + | |||
| + | <div>-> Capability to identify conclusively and quantify accurately almost any protein that has been expressed.</div> | ||
| + | |||
| + | <div>-> Systematically identify and localize modified amino acids in the polypeptide chain as well as determine the composition, stoichiometry and topology of the subunits of multiprotein complexes and even contribute to determining their structure.</div> | ||
| + | |||
| + | <div>-> Make possible the systematic analysis of the proteome to an extent that had been predicted previously</div> | ||
<p> </p> | <p> </p> | ||
| + | |||
| + | <p><a href="https://www.ncbi.nlm.nih.gov/pubmed/12634792">https://www.ncbi.nlm.nih.gov/pubmed/12634792</a></p> | ||
| + | |||
| + | <p>(From genomics to proteomics.)</p> | ||
| + | |||
| + | <p>- Proteomics would not be possible without the previous achievements of genomics, which provided the ‘blueprint’</p> | ||
| + | |||
| + | <p>of possible gene products that are the focal point of proteomics studies.</p> | ||
| + | |||
| + | <p>- The ability of mass spectrometry to identify ever smaller amounts of protein from increasingly complex mixtures is a</p> | ||
| + | |||
| + | <p>primary driving force in proteomics, as described in the review on page 198 by Aebersold and Mann.</p> | ||
| + | |||
| + | <p>Proteomics is set to have a profound impact on clinical diagnosis and drug discovery, as is fittingly reviewed by Sam Hanash on page 226, the inaugural president of HUPO.</p> | ||
| + | |||
| + | <p>Because most drug targets are proteins, it is inescapable that proteomics will enable drug discovery, development and clinical practice.</p> | ||
<p> </p> | <p> </p> | ||
| − | <p> </p> | + | <p><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=metabolomics%3A+the+apogee+of">https://www.ncbi.nlm.nih.gov/pubmed/?term=metabolomics%3A+the+apogee+of</a></p> |
| + | |||
| + | <p>(Innovation: Metabolomics: the apogee of the omics trilogy.)</p> | ||
| + | |||
| + | <p> - metabolites serve as direct signatures of biochemical activity and are therefore easier to correlate with phenotype.</p> | ||
| + | |||
| + | <p> - metabolites serve as direct signatures of biochemical activity</p> | ||
| − | <p> </p> | + | <p> - The untargeted [metabolomic] workflow is global in scope and outputs data related to comprehensive cellular metabolism.</p> |
| − | <p>& | + | <p>- In particular, it has been useful in identifying altered metabolic pathways in disease that represent novel drug targets: an evolving biomedical application referred to as ‘therapeutic metabolomics’</p> |
| − | <p> | + | <p>- Another area is in characterizing gene and protein function. In addition to successfully identifying the function of unknown genes and proteins, untargeted profiling has been applied to discover new functions for known genes and proteins.</p> |
<p> </p> | <p> </p> | ||
Revision as of 13:40, 4 December 2016
http://www.nature.com/nature/journal/v537/n7620/pdf/nature19949.pdf
(Mass-Spectrometric exploration of proteome structure and function)
-> Provide unprecedented insights into the composition, structure, function and control of the proteome, shedding light on complex biological processes and phenotypes.
- Mass-Spectrometry-based methods
https://www.ncbi.nlm.nih.gov/pubmed/12634792
(From genomics to proteomics.)
- Proteomics would not be possible without the previous achievements of genomics, which provided the ‘blueprint’
of possible gene products that are the focal point of proteomics studies.
- The ability of mass spectrometry to identify ever smaller amounts of protein from increasingly complex mixtures is a
primary driving force in proteomics, as described in the review on page 198 by Aebersold and Mann.
Proteomics is set to have a profound impact on clinical diagnosis and drug discovery, as is fittingly reviewed by Sam Hanash on page 226, the inaugural president of HUPO.
Because most drug targets are proteins, it is inescapable that proteomics will enable drug discovery, development and clinical practice.
https://www.ncbi.nlm.nih.gov/pubmed/?term=metabolomics%3A+the+apogee+of
(Innovation: Metabolomics: the apogee of the omics trilogy.)
- metabolites serve as direct signatures of biochemical activity and are therefore easier to correlate with phenotype.
- metabolites serve as direct signatures of biochemical activity
- The untargeted [metabolomic] workflow is global in scope and outputs data related to comprehensive cellular metabolism.
- In particular, it has been useful in identifying altered metabolic pathways in disease that represent novel drug targets: an evolving biomedical application referred to as ‘therapeutic metabolomics’
- Another area is in characterizing gene and protein function. In addition to successfully identifying the function of unknown genes and proteins, untargeted profiling has been applied to discover new functions for known genes and proteins.
----------------------------------------------
